Methods of treating dry eye disorders

• US 7,026,296 B2
• Filed: 08/26/2003
• Issued: 04/11/2006
• Est. Priority Date: 09/20/2002
• Status: Expired due to Fees

• Current Assignee: Novartis Ag
• Original Assignee: Alcon Incorporated
• Inventors: Gamache, Daniel A.
• Primary Examiner(s): Tate, Christopher R.
• Assistant Examiner(s): AUDET, MAURY A
• Application Number:
  US10/650,006
• Publication Number:
  US 20040058875A1
• Time in Patent Office: 959 Days
• Field of Search: 514/16
• US Class Current: 514/20.8
• CPC Class Codes: A61K 31/192 having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid cannabinoids A61K31/658
• CPC Class Codes: A61K 31/416 condensed with carbocyclic ring systems, e.g. indazole
• CPC Class Codes: A61K 31/505 Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
• CPC Class Codes: A61K 31/506 not condensed and containing further heterocyclic rings
• CPC Class Codes: A61K 31/551 having two nitrogen atoms, e.g. dilazep
• CPC Class Codes: A61K 31/616 by carboxylic acids, e.g. acetylsalicylic acid
• CPC Class Codes: A61K 38/08 Peptides having 5 to 11 amino acids A61K38/043 - A61K38/046 take precedence
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Inhibitors of cytokine synthesis in nonimmune, resident ocular surface cells are useful for treating dry eye disorders and other disorders requiring the wetting of the eye.

Claims

1. A method for the treatment of dry eye which comprises topically administering to the eye of a mammal a composition comprising a pharmaceutically acceptable carrier and a pharmaceutically effective amount of a cytokine synthesis inhibitor wherein the cytokine synthesis inhibitor is the c-jun N-terminal kinase inhibitor anthra[1,9-cd]pyrazol-6(2H)-one (SP-600125).

2. The method of claim 1 wherein the pharmaceutically effective amount of the cytokine synthesis inhibitor is 0.001–

1.0% (w/w).

3. The method of claim 1 comprising treatment of dry eye associated with refractive surgery.